Institute of Metabolism and System Research, University of Birmingham, Birmingham, UK.
AMC Hospital of Udine, Udine, Italy.
Orphanet J Rare Dis. 2018 Apr 6;13(1):50. doi: 10.1186/s13023-018-0785-7.
Niemann-Pick Type C (NPC) is a progressive and life limiting autosomal recessive disorder caused by mutations in either the NPC1 or NPC2 gene. Mutations in these genes are associated with abnormal endosomal-lysosomal trafficking, resulting in the accumulation of multiple tissue specific lipids in the lysosomes. The clinical spectrum of NPC disease ranges from a neonatal rapidly progressive fatal disorder to an adult-onset chronic neurodegenerative disease. The age of onset of the first (beyond 3 months of life) neurological symptom may predict the severity of the disease and determines life expectancy.NPC has an estimated incidence of ~ 1: 100,000 and the rarity of the disease translate into misdiagnosis, delayed diagnosis and barriers to good care. For these reasons, we have developed clinical guidelines that define standard of care for NPC patients, foster shared care arrangements between expert centres and family physicians, and empower patients. The information contained in these guidelines was obtained through a systematic review of the literature and the experiences of the authors in their care of patients with NPC. We adopted the Appraisal of Guidelines for Research & Evaluation (AGREE II) system as method of choice for the guideline development process. We made a series of conclusive statements and scored them according to level of evidence, strengths of recommendations and expert opinions. These guidelines can inform care providers, care funders, patients and their carers of best practice of care for patients with NPC. In addition, these guidelines have identified gaps in the knowledge that must be filled by future research. It is anticipated that the implementation of these guidelines will lead to a step change in the quality of care for patients with NPC irrespective of their geographical location.
尼曼-匹克 C 型(NPC)是一种进行性且危及生命的常染色体隐性遗传病,由 NPC1 或 NPC2 基因突变引起。这些基因的突变与内体溶酶体运输异常有关,导致溶酶体中多种组织特异性脂质的积累。NPC 疾病的临床谱范围从新生儿迅速进行性致命疾病到成人发病的慢性神经退行性疾病。首次(3 个月后)出现神经系统症状的发病年龄可能预测疾病的严重程度,并决定预期寿命。NPC 的估计发病率为~1:100,000,由于疾病罕见,导致误诊、延迟诊断和获得良好治疗的障碍。出于这些原因,我们制定了临床指南,为 NPC 患者定义了标准护理,促进了专家中心和家庭医生之间的共同护理安排,并为患者提供了支持。这些指南中的信息是通过对文献的系统回顾和作者在 NPC 患者护理方面的经验获得的。我们采用评估指南研究与评估(AGREE II)系统作为指南制定过程的首选方法。我们提出了一系列结论性陈述,并根据证据水平、建议强度和专家意见对其进行评分。这些指南可以为护理提供者、护理资金提供者、患者及其照顾者提供 NPC 患者最佳护理实践的信息。此外,这些指南还确定了必须通过未来研究填补的知识空白。预计这些指南的实施将导致 NPC 患者的护理质量发生重大变化,无论其地理位置如何。